What’s Trending in Monoclonal Antibodies (Market by Structure [Chimeric, Humanized], by Target [EGFR, TNF, HER2, CD20,PD-1, Other] and by Disease [Autoimmune, Oncology, Neurological, Other])

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARYOVERVIEW

Figure 1-1: Monoclonal Antibody Market Development, 1986-2022

SCOPE AND METHODOLOGYMARKET SUMMARY

Figure 1-2: Monoclonal Antibody Market, 2017-2022 ($ millions)

CHAPTER TWO: INTRODUCTIONTHE DEVELOPMENT OF MONOCLONAL ANTIBODIES

Figure 2-1: Monoclonal Antibody Approvals by Year, FDA and EMA, 1990 through December 2017

NAMING MONOCLONAL ANTIBODIES

Table 2-1: Monoclonal Antibody Source Identifiers

Table 2-2: Monoclonal Antibody Disease or Target Class Identifiers

Table 2-3: Examples of Monoclonal Antibodies by Name Origin

New Monoclonal Antibody Nomenclature Rules

Table 2-4: USAN Requirements for Monoclonal Antibodies

DEVELOPMENT OUTLOOK

Table 2-5: Monoclonal Antibody Development Pipeline by Therapeutic Class and Phase, 2017 (Oncology, Autoimmune, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Cardiovascular Disease/Blood Disorders, Genetic Disorders, Others, Total)

Figure 2-2: Monoclonal Antibody Development Pipeline by Therapeutic Class and Phase, 2017 (Oncology, Autoimmune, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Cardiovascular Disease/Blood Disorders, Genetic Disorders, Others)

Figure 2-3: Monoclonal Antibody Development Pipeline, Distribution of Projects by Therapeutic Class, 2017 (Oncology, Autoimmune, Respiratory Disorders, Neurological Disorders, Infectious Diseases, Cardiovascular Disease/Blood Disorders, Genetic Disorders, Others)

Figure 2-4: Monoclonal Antibody Development Pipeline, Distribution of Projects by Phase, 2017 (Registration, Phase I, Phase II, Phase III)

CHAPTER THREE: MONOCLONAL ANTIBODY MARKETS BY STRUCTURE

Figure 3-1: Monoclonal Antibodies by Structure – Mouse, Chimeric, Humanized, Human

MARKET OVERVIEW

Table 3-1: Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 ($ millions) (Chimeric, Humanized, Human, Others, Total)

Figure 3-2: Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 ($ millions) (Chimeric, Humanized, Human, Others)

Figure 3-3: Monoclonal Antibody Market Distribution by Structure, 2017 (%) (Chimeric, Humanized, Human, Others)

Figure 3-4: Monoclonal Antibody Market Distribution by Structure, 2022 (%) (Chimeric, Humanized, Human, Others)

Chimeric

Table 3- 2: Leading Products: Chimeric Structure mAb Market, 2017-2022 ($ millions)

Humanized

Table 3-3: Leading Products: Humanized Structure mAb Market, 2017-2022 ($ millions)

Human

Table 3-4: Leading Products: Human Structure mAb Market, 2017-2022 ($ millions)

CHAPTER FOUR: MONOCLONAL ANTIBODY MARKETS BY TARGETMARKET OVERVIEW

Figure 4-1: Monoclonal Antibodies by Target – TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6 Examples

Table 4-1: Monoclonal Antibody Market by Target, 2017 and Forecast 2022 ($ millions) (TNF, VEGF, HER2, PD-1, CD20, IL12/IL23, TNFSF11, IL17, EGFR, IL6, PD-L1, Others, Total)

Figure 4-2: Monoclonal Antibody Market by Target, 2017 and Forecast 2022 ($ millions) (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others)

Figure 4-3: Monoclonal Antibody Market Distribution by Target, 2017 (%) (TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6, Others)

Figure 4-4: Monoclonal Antibody Market Distribution by Target, 2022 (%) (TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6, Others)

CHAPTER FIVE: MONOCLONAL ANTIBODY MARKETS BY INDICATIONMARKET OVERVIEW

Table 5-1: Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 ($ millions) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other, Total)

Figure 5-1: Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 ($ millions) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)

Figure 5-2: Monoclonal Antibody Market Distribution by Indication, 2017 (%) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)

Figure 5-3: Monoclonal Antibody Market Distribution by Indication, 2022 (%) (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)

Autoimmune Diseases

Table 5-2: Rheumatoid Arthritis mAb Market, 2017-2022 ($ millions)

Table 5-3: Crohn’s Disease/Ulcerative Colitis mAb Market, 2017-2022 ($ millions)

Table 5-4: Psoriasis mAb Market, 2017-2022 ($ millions)

Table 5-5: Other Autoimmune Disease mAb Market, 2017-2022 ($ millions)

Oncology Indications

Table 5-6: Cancer Treatment mAb Market by Type, 2017-2022 ($ millions) (Breast Cancer, Colon Cancer, Lymphoma, Leukemia, Myeloma, Melanoma)

Table 5-7: Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales (millions $)

Figure 5-4: Top 10 Cancer Indicated Monoclonal Antibodies, 2016 and 2017 Sales (millions $)

Neurological Indications

Table 5-8: Multiple Sclerosis mAb Market, 2017-2022 ($ millions)

Respiratory Treatments

Table 5-9: Asthma mAb Market, 2017-2022 ($ millions)

OTHER AREAS OF TREATMENT

Table 5-10: Macular Degeneration mAb Market, 2017-2022 ($ millions)

CHAPTER SIX: MARKET SUMMARYMARKET INFLUENCESGlobal Demographics

Table 6-1: Global Population, through 2050 (population in millions)

Figure 6-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Chronic Diseases

Figure 6-2: Mortality: Chronic vs. Acute, 2015

Cost Containment

Table 6-2: The Cost of Monoclonal Antibodies (Soliris, Ilaris, Erbitux, Opdivo, Avastin, Yervoy, Stelara, Xolair, Perjeta, Tysabri, Cosentyx, Simponi, Vectibix, Herceptin, Humira, Entyvio, Rituxan, Synagis, Remicade)

REIMBURSEMENT LANDSCAPE: A DECIDING FACTOR FOR SUCCESSTHE BIOSIMILAR MOVEMENTREGIONAL MARKET OVERVIEW

Table 6-3: Monoclonal Antibody Market Summary by Geographical Region, 2017-2022 ($ millions) (United States, Europe, Rest of World, Global Market)

Figure: 6-3: Monoclonal Antibody Market Summary by Geographic Region, 2017 ($ millions) (United States, Europe, Rest of World)

LEADING PRODUCTS

Table 6-4: Leading Monoclonal Antibodies based on 2017 Sales ($ millions)

MARKET BREAKDOWN OF MONOCLONAL ANTIBODIES

Figure 6-4: Monoclonal Antibody Market by Structure, 2017 and 2022 ($ millions) (Chimeric, Humanized, Human, Others)

Figure 6-5: Monoclonal Antibody Market by Target, 2017 and 2022 ($ millions) (TNF, CD20, HER2, VEGF, EGFR, PD-L1, PD-1, TNFSF11, IL12/IL23, IL17, IL6, Others)

Figure 6-6: Monoclonal Antibody Market by Indication, 2017 and 2022 ($ millions) (Rheumatoid Arthritis, Breast Cancer, Melanoma, Crohn’s Disease/Ulcerative Colitis, Colon Cancer, Lymphoma, Psoriasis, Macular Degeneration, Asthma, Multiple Sclerosis, Osteoporosis, Myeloma, RSV, Leukemia, Other Indications)

COMPETITOR SUMMARY

Genentech/Roche

AbbVie

Janssen Biotech/J&J

Bristol-Myers Squibb

Merck & Co

Novartis

Amgen

Alexion

Biogen

Eli Lilly & Co.

Table 6-5: Monoclonal Antibody Competitor Market Share, 2017 ($ millions)

CHAPTER SEVEN: COMPANY PROFILESABBVIE

Table 7-1: AbbVie Corporate Summary

ABLYNX

Table 7-2: Ablynx Corporate Summary

AGENSYS

Table 7-3: Agensys (with Astellas) Corporate Summary

ALDER BIOPHARMACEUTICALS

Table 7-4: Alder Biopharmaceuticals Corporate Summary

ALEXION PHARMACEUTICALS

Table 7-5: Alexion Pharmaceuticals Corporate Summary

ALLERGAN

Table 7-6: Allergan Corporate Summary

AMGEN

Table 7-7: Amgen Corporate Summary

APTEVO THERAPEUTICS

Table 7-8: Aptevo Corporate Summary

ASTRAZENECA/MEDIMMUNE

Table 7-9: AstraZeneca/MedImmune Corporate Summary

BAYER

Table 7-10: Bayer Corporate Summary

BIOCON LTD

Table 7-11: Biocon Corporate Summary

BIOGEN INC.

Table 7-12: Biogen Corporate Summary

BIOINVENT INTERNATIONAL

Table 7-13: BioInvent Corporate Summary

BIOTEST AG

Table 7-14: Biotest AG Corporate Summary

BOEHRINGER INGELHEIM GMBH

Table 7-15: Boehringer Ingelheim Corporate Summary

CBT PHARMACEUTICALS

Table 7-16: CBT Corporate Summary

CELGENE

Table 7-17: Celgene Corporate Summary

CELLDEX THERAPEUTICS

Table 7-18: Celldex Therapeutics Corporate Summary

CELLTRION, INC.

Table 7-19: Celltrion Corporate Summary

COHERUS BIOSCIENCES, INC

Table 7-20: Coherus Biosciences Corporate Summary

CYTODYN

Table 7-21: CytoDyn Corporate Summary

EISAI

Table 7-22: Eisai Corporate Summary

ELEVEN BIOTHERAPEUTICS

Table 7-23: Eleven Biotherapeutics Corporate Summary

ELI LILLY & CO.

Table 7-24: Eli Lilly & Co. Corporate Summary

FIBROGEN INC.

Table 7-25: FibroGen Inc. Corporate Summary

FIVE PRIME THERAPEUTICS

Table 7-26: Five Prime Therapeutics Corporate Summary

FUJIFILM KYOWA KIRIN BIOLOGICS

Table 7-27: Fujifilm Kyowa Kirin Biologics Corporate Summary

GENMAB A/S

Table 7-28: Genmab A/S Corporate Summary

GILEAD SCIENCES

Table 7-29: Gilead Sciences Corporate Summary

GLAXOSMITHKLINE PLC

Table 7-30: GlaxoSmithKline Corporate Summary

HUMANIGEN, INC. (PREVIOUSLY KALOBIOS PHARMACEUTICALS)

Table 7-31: Humanigen Inc. Corporate Summary

IMMUNE PHARMACEUTICALS

Table 7-32: Immune Pharmaceuticals Corporate Summary

IMMUNOGEN INC.

Table 7-33: ImmunoGen Inc. Corporate Summary

IMMUNOMEDICS INC.

Table 7-34: Immunomedics Inc. Corporate Summary

INNATE PHARMA

Table 7-35: Innate Pharma Corporate Summary

INTERVEXION THERAPEUTICS

Table 7-36: InterveXion Therapeutics Corporate Summary

JOHNSON & JOHNSON

Table 7-37: Johnson & Johnson Corporate Summary

KYOWA HAKKO KIRIN CO, LTD

Table 7-38: Kyowa Hakko Kirin Corporate Summary

MACROGENICS

Table 7-39: MacroGenics Corporate Summary

MAPP BIOPHARMACEUTICAL

Table 7-40: Mapp Corporate Summary

MERCK & COMPANY

Table 7-41: Merck Corporate Summary

MERRIMACK PHARMACEUTICALS

Table 7-42: Merrimack Corporate Summary

MOMENTA PHARMACEUTICALS INC

Table 7-43: Momenta Pharmaceuticals Corporate Summary

MORPHOSYS

Table 7-44: MorphoSys Corporate Summary

MORPHOTEK

Table 7-45: Morphotek Corporate Summary

MYLAN N.V.

Table 7-46: Mylan Corporate Summary

NASCENT BIOTECH

Table 7-47: Nascent Biotech Corporate Summary

NEURIMMUNE

Table 7-48: Neurimmune Corporate Summary

NORDIC NANOVECTOR

Table 7-49: Nordic Nanovector Corporate Summary

NOVARTIS/SANDOZ

Table 7-50: Novartis/Sandoz Corporate Summary

NOVIMMUNE SA

Table 7-51: Novimmune SA Corporate Summary

ONCOMED PHARMACEUTICALS

Table 7-52: OncoMed Pharmaceuticals Corporate Summary

ONCOQUEST

Table 7-53: OncoQuest Corporate Summary

ONCTERNAL THERAPEUTICS

Table 7-54: Oncternal Therapeutics Corporate Summary

PFIZER, INC.

Table 7-55: Pfizer Corporate Summary

REGENERON PHARMACEUTICALS

Table 7-56: Regeneron Corporate Summary

ROCHE

Table 7-57: Roche Corporate Summary

SAMSUNG BIOEPIS CO LTD

Table 7-58: Samsung Bioepis Corporate Summary

SANOFI

Table 7-59: Sanofi Corporate Summary

SEATTLE GENETICS

Table 7-60: Seattle Genetics Corporate Summary

SHIRE PLC

Table 7-61: Shire PLC Corporate Summary

SORRENTO THERAPEUTICS

Table 7-62: Sorrento Therapeutics Corporate Summary

TAIMED BIOLOGICS

Table 7-63: TaiMed Biologics Corporate Summary

TAKEDA ONCOLOGY

Table 7-64: Takeda Oncology Corporate Summary

TESARO

Table 7-65: TESARO Corporate Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD

Table 7-66: Teva Corporate Summary Corporate Summary

TG THERAPEUTICS

Table 7-67: TG Therapeutics Corporate Summary

THROMBOGENICS

Table 7-68: ThromboGenics Corporate Summary

UCB S.A.

Table 7-69: UCB S.A. Corporate Summary

UNUM THERAPEUTICS

Table 7-70: Unum Therapeutics Corporate Summary

VITAERIS

Table 7-71: Vitaeris Corporate Summary

XBIOTECH

Table 7-72: XBiotech Corporate Summary

XENCOR

Table 7-73: Xencor Corporate Summary

XOMA

Table 7-74: XOMA Corporate Summary

Y-MABS THERAPEUTICS

Table 7-75: Y-mAbs Therapeutics Corporate Summary